November 19, 2026
Health news, explained with evidence
LIVE
JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities

Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial

🔬 Research 2 min read 👁 0

A phase II clinical trial suggests the oral medication NA-931 may facilitate significant weight loss while potentially preserving lean muscle mass. The drug targets four distinct receptors, distinguishing it from current GLP-1 based weight management therapies.

Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial🔬Research

Photo: medpagetoday.com

Key points

  • NA-931 targets four receptors: GLP-1, GIP, glucagon, and IGF-1.
  • Participants at the 150 mg dose lost nearly 14% of their body weight in 13 weeks.
  • The medication showed lower rates of nausea and vomiting compared to current market-leading weight loss drugs.

A new investigational oral drug, NA-931, demonstrated substantial weight reduction in a randomized phase II clinical trial involving 125 adults with obesity or weight-related comorbidities. Presented at the ObesityWeek annual meeting, the study found that participants taking the highest dose of 150 mg experienced a 13.8% reduction in body weight over 13 weeks, compared to a 1.9% reduction in the placebo group.

The study, led by researchers at Biomed Industries, highlighted that lean mass decreased by only 1.7% during the trial period. This finding is notable when compared to existing GLP-1 and dual-agonist therapies, which have historically been associated with higher proportions of lean mass loss relative to total weight reduction. Researchers noted that preserving muscle mass is particularly important for long-term metabolic health, especially as individuals age.

What to know: The trial utilized DEXA scans to estimate lean soft tissue changes, though these measurements do not directly confirm muscle function. The drug, which targets IGF-1, GLP-1, GIP, and glucagon receptors, also showed a favorable safety profile with gastrointestinal side effects occurring at rates only slightly higher than those observed in the placebo group. As this is a phase II study with a relatively small sample size, further large-scale phase III trials are required to confirm efficacy and long-term safety. Always consult with a healthcare provider before considering new medical treatments for weight management.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/obesityweek/123955 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.